Capecitabine (trade name: Xeloda®) is an orally-administered chemotherapeutical professional utilized in the professional assistance of metastatic breast and colorectal cancers. These are enzymatically converted to fluorouracil in the body, in which it inhibits DNA synthesis and slows growth of neoplasm tissue.

Indications

Capecitabine is FDA-approved for:

Metastatic Colorectal Cancer

Utilized when foremost-line monotherapy, whenever appropriate.

Metastatic Breast Cancer

Utilized within combination by owning docetaxel, after failure of anthracycline-based professional assistance.

Utilized when monotherapy, in case a patient has failed paclitaxel-depending coarse of action, & in case anthracycline-based coarse of action has either failed or even can't exist as continued for more reasons (we.e., a patient has already received a maximal life-time dose of an anthracycline).

Dose

A common starting dose is 2,500 mg/m2/day within 2 divided drugs, Xii hours apart. Of these period includes 2 weeks of coarse of action followed by seven days forswearing coarse of action. Rounds may be repeated each trinity weeks.

Dose Adjustments

For modest nephritic disfunction (creatinine clearance 30-50 mL/min), it is recommended to reduce dose by 25%.

For severe nephritic disfunction (creatinine clearance <30 mL/min), treatment is not recommended.

No recommendation for hepatic disfunction.

For older patients, moo drugs can be mandatory due to higher incidences of good adverse responses.

Administration

Require orally by owning fluids, in Half-hour when the meal.

Potential Adverse Reactions (Major)

Cardiovascular: EKG changes, myocardial infarction, angina (these may be supplementary commons inside patients by having pre-existing coronary artery disease)

Dermatologic: H&-foot syndrome (numbness, tingling, anguish, redness, or even blistering of the palms of the paws and soles of the feet)

Gastrointestinal: Diarrhea (sometimes severe), nausea, stomatitis

Haematological: Neutropenia, anemia, thrombocytopenia

Hepatic: Hyperbilirubinemia

Drug Interactions

Capecitabine will interact by owning warfarin and increase bleeding risk. It is recommended to observe curdling levels (INR) closely and adjust coumadin drugs suitably.

Capecitabine will inhibit cytochrome CYP2C9 enzyme, and so increase levels of substrates such as phenytoin. It is recommended to monitor dilantinside levels in patients ingesting two medications. More substrates of CYP2C9 might likewise become affected. Evaluate based on data from clinical judgment.

Very much like fluorouracil, a incidental to have of leucovorin may increase both a efficaciousness & a toxicity of capecitabine.

Pregnancy / Lactation Information

Capecitabine is pregnancy category D. Women of childbearing likely come advised to make sure your not becoming pregnant when utilizing capecitabine.

Important numbers of capecitabine can be excreted into a breast milk. It is recommended to discontinue nursing when utilizing capecitabine.

Product Information

Capecitabine (when br&-title Xeloda) is available inside lightly peach 150 mg tablets and peach D mg tablets.